The government issued a compulsory license to Geropharm for the diabetes drug Semavik
[ad_1]
The government issued a compulsory license to the pharmaceutical company Geropharm for the diabetes drug Semavik (an analogue of the Danish Ozempic). The company will be able to produce it without the consent of the patent owner throughout 2024, they reported TASS in the press service of “Geropharm”.
According to the company’s general director Peter Rodionov, Geropharm has production facilities that will allow it to produce the required amount of the drug to meet the needs of the Russian market.
“Geropharm managed to develop the first Russian analogue of Ozempic, Semavik, in the shortest possible time. Its introduction to the market will allow uninterrupted provision of the country’s residents with a vital drug for effective compensation of the disease,” said Mr. Rodionov and noted that in Russia more than 4.5 million people suffer from diabetes.
In March 2023, Ozempic, produced by the Danish Novo Nordisk, ceased to be sold in Russian pharmacies. Geropharm contacted Novo Nordisk with letters about concluding a license agreement for the use of patents, but did not receive a response. The first batch of Semavik will amount to 250–300 thousand packages and will be released before the end of 2023. The Ministry of Health and the Federal Antimonopoly Service determined the cost of the drug at 4279.5 rubles. (without VAT). “Semavik” is planned to be produced at a plant in Obolensk based on the Chinese ZPC substance.
Read more about Semavik in the Kommersant article “Russia is prescribed a hypoglycemic drug”.
[ad_2]
Source link
